Michel Vierboom

3.7k citations

46 papers · 2.9k indexed · 1 hit paper · h-index 26

Immunology top 1%
Molecular Biology top 10%
Epidemiology top 5%
Oncology top 5%
Genetics top 5%

Co-authors: W. Martin Kast Cornelis J.M. Melief Mariet C.W. Feltkamp Jan W. Drijfhout Jan ter Schegget Henk L. Smits B. M. de Jongh René Minnaar
Topics: Immunotherapy and Immune Responses (21 papers)Rheumatoid Arthritis Research and Therapies (11 papers)T-cell and B-cell Immunology (10 papers)
Cited by: Immunology Oncology Epidemiology
Journals: Nature Medicine The Journal of Experimental Medicine Circulation Research
Partner nations: Netherlands United States France

In The Last Decade

Michel Vierboom

46 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

1993 709 citations Mariet C.W. Feltkamp, Michel Vierboom et al. European Journal of Immunology profile →

Peers

Countries citing papers authored by Michel Vierboom

Since Specialization

Citations

This map shows the geographic impact of Michel Vierboom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Vierboom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Vierboom more than expected).

Fields of papers citing papers by Michel Vierboom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Vierboom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Vierboom. The network helps show where Michel Vierboom may publish in the future.

Co-authorship network of co-authors of Michel Vierboom

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Vierboom. A scholar is included among the top collaborators of Michel Vierboom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Vierboom. Michel Vierboom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection 2021 ·Cell Reports Medicine ·Karin Dijkman,Nacho Aguiló,Charelle Boot,Sam Hofman,Claudia C. Sombroek,Richard A. W. Vervenne,Clemens H. M. Kocken,Dessislava Marinova,Jelle Thole,Esteban Rodríguez,Michel Vierboom,Krista G. Haanstra,Eugenia Puentes,Carlos Martı́n,Frank A. W. Verreck	33
2	Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques 2019 ·Nature Medicine ·Karin Dijkman,Claudia C. Sombroek,Richard A. W. Vervenne,Sam Hofman,Charelle Boot,Edmond J. Remarque,Clemens H. M. Kocken,Tom H. M. Ottenhoff,Ivanela Kondova,(unknown),Krista G. Haanstra,Michel Vierboom,Frank A. W. Verreck	194
3	Pain Relief in Nonhuman Primate Models of Arthritis 2017 ·Methods in molecular biology ·Michel Vierboom,(unknown),(unknown),(unknown),Jaco Bakker	5
4	Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis 2017 ·Arthritis Research & Therapy ·Marije K. Verheul,Michel Vierboom,Bert A. ‘t Hart,René E. M. Toes,Leendert A. Trouw	18
5	Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis 2015 ·Clinical & Experimental Immunology ·Michel Vierboom,(unknown),Yolanda S. Kap,Caroline Mary,Nicolas Poirier,Bert A. ‘t Hart,Bernard Vanhove	20
6	Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis 2015 ·PubMed ·Lisette Bevaart,(unknown),Michel Vierboom,(unknown),Ivanela Kondova,(unknown),Bernd Hauck,J. Fraser Wright,Paul P. Tak,Margriet J. Vervoordeldonk	16
7	The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis 2015 ·Arthritis Research & Therapy ·Maarten Van Roy,Cedric Ververken,Els Beirnaert,(unknown),Joost A. Kolkman,Michel Vierboom,(unknown),Bert ’t Hart,Sofie Poelmans,(unknown),Alex Hemeryck,(unknown),Judith Baumeister,Hans Ulrichts	145
8	Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies 2014 ·Drug Discovery Today ·Bert A. ‘t Hart,S. Anwar Jagessar,Yolanda S. Kap,Krista G. Haanstra,Ingrid H.C.H.M. Philippens,Ché Serguera,Jan A. M. Langermans,Michel Vierboom	14
9	Comparative analysis of inflammatory infiltrates in collagen-induced arthritis, kidney graft rejection and delayed-type hypersensitivity in non-human primates 2012 ·Inflammation Research ·Margreet Jonker,Jacqueline Wubben,Krista G. Haanstra,Michel Vierboom,Bert ’t Hart	4
10	New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis 2012 ·Expert Opinion on Drug Discovery ·Michel Vierboom,(unknown),Bert A. ‘t Hart	4
11	Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis 2010 ·Arthritis Research & Therapy ·Michel Vierboom,(unknown),Ivanela Kondova,Bert A. ‘t Hart	27
12	The significance of non-human primates as preclinical models of human arthritic disease 2008 ·Expert Opinion on Drug Discovery ·Michel Vierboom,(unknown),Ivanela Kondova,Bert A. ‘t Hart	8
13	Preclinical models of arthritic disease in non-human primates 2007 ·Drug Discovery Today ·Michel Vierboom,Margreet Jonker,Paul P. Tak,Bert A. ‘t Hart	44
14	Monotherapy with the vitamin D3 analogue MC1288 does not result in prolonged kidney allograft survival in rhesus monkeys 2006 ·Transplant International ·Michel Vierboom,Cecilia Johnsson,Bert ’t Hart,Margreet Jonker	5
15	Modeling human arthritic diseases in nonhuman primates. 2005 ·Arthritis Research & Therapy ·Michel Vierboom,Margreet Jonker,Ronald E. Bontrop,Bert ’t Hart	50
16	BLOCKING THE CD80 AND CD86 COSTIMULATION MOLECULES: LESSONS TO BE LEARNED FROM ANIMAL MODELS 2002 ·Transplantation ·Margreet Jonker,Miriam A. Ossevoort,Michel Vierboom	24
17	p53: A Potential Target Antigen for Immunotherapy of Cancer 2000 ·Annals of the New York Academy of Sciences ·Rienk Offringa,Michel Vierboom,Sjoerd H. van der Burg,Lorne Erdile,Cornelis J.M. Melief	49
18	Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL 2000 ·International Journal of Cancer ·Michel Vierboom,Gerard M.J. Bos,(unknown),Rienk Offringa,Cornelis J.M. Melief	37
19	Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors 1995 ·European Journal of Immunology ·Mariet C.W. Feltkamp,Gienke R. Vreugdenhil,Michel Vierboom,(unknown),Sjoerd H. van der Burg,Jan ter Schegget,Cornelis J.M. Melief,W. Martin Kast	145
20	Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes 1993 ·European Journal of Immunology ·Hans W. Nijman,J. G. A. Houbiers,Michel Vierboom,Sjoerd H. van der Burg,Jan W. Drijfhout,J. D‘Amaro,Peter Kenemans,Cornelis J.M. Melief,W. Martin Kast	176

About Michel Vierboom

Michel Vierboom is a scholar working on Immunology, Rheumatology and Transplantation, having authored 46 papers that have together received 2.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (21 papers), Rheumatoid Arthritis Research and Therapies (11 papers) and T-cell and B-cell Immunology (10 papers). The work is most often cited by research in Immunology (2.2k citations), Oncology (642 citations) and Epidemiology (657 citations). Michel Vierboom has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include W. Martin Kast, Cornelis J.M. Melief, Mariet C.W. Feltkamp, Jan W. Drijfhout, Jan ter Schegget, Henk L. Smits, B. M. de Jongh, René Minnaar, Hans W. Nijman and Rienk Offringa. Their work appears in journals such as Nature Medicine, The Journal of Experimental Medicine and Circulation Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact